GlassScriptPhysician profile
Megan A Durkin
NPI 1093494643
$3,878.41
in general payments reported to CMS, 2019-2025
19 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $130 · 2024: $1,910 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.14 | 2023-2025 | |
| Novo Nordisk INC | $433.36 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $420.80 | 2023-2025 | Evenity, Repatha, Otezla |
| Axsome Therapeutics, INC. | $329.21 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $328.81 | 2024-2025 | Farxiga, Airsupra |
| Pfizer INC. | $223.43 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $207.42 | 2025 | Rexulti |
| Exact Sciences Corporation | $193.97 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $168.30 | 2024-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.81 | 2025 | Caplyta |
| Astellas Pharma US INC | $94.70 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $92.25 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Almatica Pharma LLC | $77.54 | 2023-2025 | Loreev Xr |
| Bausch Health US, LLC | $61.04 | 2025 | Wellbutrin, Aplenzin |
| Ardelyx, INC. | $56.12 | 2024-2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $52.74 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $42.65 | 2024-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $37.81 | 2024 | Invega Sustenna |
| Acella Pharmaceuticals, LLC | $20.31 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Durkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.